Welcome to our dedicated page for Cullinan Oncology news (Ticker: CGEM), a resource for investors and traders seeking the latest updates and insights on Cullinan Oncology stock.
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a clinical-stage biopharmaceutical company developing potential first- or best-in-class therapies for autoimmune diseases and cancer. The CGEM news feed highlights the company’s ongoing clinical progress, regulatory interactions, and scientific presentations across its portfolio of T cell engagers and targeted therapies.
News updates frequently cover clinical trial data for key assets such as CLN-049, an FLT3xCD3 bispecific T cell engager in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, and CLN-978, a CD19xCD3 bispecific T cell engager being studied in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s disease. Releases detail efficacy signals, safety profiles, B cell depletion data, and outcomes in high-risk patient subsets, often presented at major medical meetings like ASH, ASCO, ESMO, ACR, and WCLC.
The CGEM news section also features updates on zipalertinib (CLN-081/TAS6417), an EGFR tyrosine kinase inhibitor for non-small cell lung cancer with EGFR exon 20 insertion and other uncommon mutations, developed in collaboration with Taiho Oncology and Taiho Pharmaceutical. These stories include information on Breakthrough Therapy Designation, rolling New Drug Application submissions, and data from REZILIENT trials, including cohorts with active brain metastases.
Investors and followers of Cullinan Therapeutics can use this page to review corporate updates, SEC-related announcements furnished via press release, and portfolio decisions such as program prioritizations or discontinuations. For anyone tracking CGEM, the news feed provides a consolidated view of the company’s disclosed milestones, scientific progress, and regulatory steps across its autoimmune and oncology programs.
On August 1, 2022, Cullinan Oncology (Nasdaq: CGEM) announced the granting of stock option awards for 137,700 shares to four new employees as part of an inducement arrangement, complying with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $13.30, matching the closing stock price on the same day. Each option vests over four years, with the first 25% vesting after one year. This move aims to attract talent and incentivize performance within the company.
Cullinan Oncology (Nasdaq: CGEM) has announced that its CFO, Jeff Trigilio, will participate in key investor conferences this August. He will engage in a fireside chat at the BTIG Biotechnology Conference on August 8, 2022, at 1:00 p.m. EDT, followed by a presentation at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 3:30 p.m. EDT. A live webcast of the Canaccord presentation will be available on the company's investor relations website. Interested investors can schedule one-on-one meetings through event representatives.
Cullinan Oncology, Inc. (NASDAQ: CGEM) announced that its Chief Scientific Officer, Patrick Baeuerle, Ph.D., will present a keynote at the William Blair Biotech Focus Conference on July 12, 2022. The presentation, titled “Multispecific Protein Therapies: Where We’ve Been and Where We’re Going?”, is set for 1:00 p.m. EDT. Cullinan's management will also hold one-on-one meetings with attendees. The company focuses on developing targeted cancer therapies, emphasizing innovation and scientific excellence across a diversified pipeline.
Cullinan Oncology, Inc. (Nasdaq: CGEM) announced the grant of stock options to two new employees, totaling 70,000 shares, outside its 2021 Stock Option and Incentive Plan. The exercise price is set at $12.93, matching the closing price on July 1, 2022. Each option features a ten-year term and vests over four years, with 25% vesting after one year and the remainder in equal installments over the following 36 months, contingent on continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent within the company.
Cullinan Oncology has finalized its agreement with Taiho Pharmaceutical, receiving an upfront payment of $275 million and the potential for $130 million in milestone payments related to CLN-081/TAS6417, an EGFR inhibitor for NSCLC. Taiho will hold global rights outside the U.S. and both companies will co-develop the drug in the U.S., sharing profits equally. The compound has received Breakthrough Therapy Designation from the FDA and is currently in a Phase 1/2a clinical trial.
Cullinan Oncology (Nasdaq: CGEM) announced the granting of stock options for 174,000 shares to four new employees as an inducement for their hiring. These options, which have an exercise price of $11.34 per share—equal to the closing price on June 1, 2022—are tied to the Nasdaq Listing Rule 5635(c)(4). Each option has a ten-year term and will vest over four years, with 25% vesting on the first anniversary. This move is aimed at attracting talent and enhancing the company's position in the biopharmaceutical sector focused on cancer therapies.
Cullinan Oncology (NASDAQ: CGEM) announced updated results from its Phase 1/2a study of CLN-081 for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Key findings include a median duration of response exceeding 21 months and a median progression-free survival of 12 months at the 100 mg BID dose. The overall response rate was confirmed at 41% among treated patients. The drug displayed favorable safety and tolerability in heavily pre-treated patients. Further data will be presented at the 2022 ASCO Annual Meeting.
Cullinan Oncology (Nasdaq: CGEM) announced an investor briefing on June 4, 2022, at 8:00 a.m. EDT during the ASCO Annual Meeting to discuss updated data from the Phase 1/2a study of CLN-081/TAS6417 for non-small cell lung cancer patients with EGFR Exon 20 insertion mutations. This briefing follows a presentation of the data on June 3, 2022, during an ASCO oral abstract session. CLN-081/TAS6417 is an oral, irreversible EGFR inhibitor specifically targeting EGFR exon 20 insertion mutations. A strategic collaboration has been established with Taiho Pharmaceutical for its development.
Cullinan Oncology (NASDAQ: CGEM) announced that CFO Jeff Trigilio will present at the H.C. Wainwright Global Investment Conference from May 23-25, 2022, in Miami and online. The presentation will be available on-demand starting May 24 at 7:00 a.m. ET on the company’s investor relations website.
Cullinan focuses on developing targeted therapies for cancer, leveraging unique partnerships and a diverse pipeline aimed at enhancing patient care.
Cullinan Oncology (CGEM) announced a significant co-development agreement with Taiho Pharmaceutical for CLN-081, receiving $275 million upfront and potential regulatory milestone payments of $130 million. The company reported cash and investments totaling $685 million, ensuring operational funding through 2026. Key pipeline updates include ongoing Phase I trials for CLN-049 and CLN-619, with initial data expected mid-2023, and IND submissions for CLN-617 and CLN-978 anticipated in the first half of 2023. The net loss for Q1 2022 was reduced to $12.9 million from $34.2 million in Q4 2021.
FAQ
What is the current stock price of Cullinan Oncology (CGEM)?
What is the market cap of Cullinan Oncology (CGEM)?
